Evidence map›Paper›PMID 34967265›Full record

ArticleBioengineered2022

Co-treatment with miR-21-5p inhibitor and Aurora kinase inhibitor reversine suppresses breast cancer progression by targeting sprouty RTK signaling antagonist 2.

Yue Zhang, Yaoyi Wang, Jun Xue, Wanping Liang, Zhisheng Zhang, Xiuming Yang, Zhifei Qiao, Yang Jiang, Junping Wang, Xuchen Cao and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioengineered, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 3 countries.

Yue ZhangDepartment of Thoracic Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Yaoyi WangDepartment of Radiology, Tianjin Medical University General Hospital, Tianjin, China.
Jun XueDepartment of Mammography Surgery, The First Affiliated Hospital of Hebei North University, Zhangjiakou, China.
Wanping LiangDepartment of Mammography Surgery, The First Affiliated Hospital of Hebei North University, Zhangjiakou, China.
Zhisheng ZhangDepartment of Mammography Surgery, The First Affiliated Hospital of Hebei North University, Zhangjiakou, China.
Xiuming YangDepartment of Mammography Surgery, The First Affiliated Hospital of Hebei North University, Zhangjiakou, China.
Zhifei QiaoDepartment of Mammography Surgery, The First Affiliated Hospital of Hebei North University, Zhangjiakou, China.
Yang JiangDepartment of Mammography Surgery, The First Affiliated Hospital of Hebei North University, Zhangjiakou, China.
Junping WangDepartment of Radiology, Tianjin Medical University General Hospital, Tianjin, China.
Xuchen CaoNational Clinical Research Center for Cancer, Tianjin, China.
Peng ChenDepartment of Thoracic Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Hebei North University · CNTianjin Medical University Cancer Institute and Hospital · CNCRUK Lung Cancer Centre of Excellence · GBTianjin Medical University General Hospital · CNTianjin University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Numerous studies have reported the regulatory effects of miR-21-5p and reversine in human breast cancer (HBC). However, the mechanism of reversine and miR-21-5p has not been fully investigated in HBC. The aim of the current study was to assess the mechanism of action of reversine, with or without miR-21-5p, in HBC progression. Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and Western blot results confirmed the upregulation of miR-21-5p and downregulation of sprouty RTK signaling antagonist 2 (SPRY2) in HBC. Bioinformatics analysis and luciferase assay identified the correlation between miR-21-5p and SPRY2. Cell function experiment results indicated a decrease in migration, proliferation, and invasion of HBC cells treated with miR-21-5p inhibitor and reversine; however, an increase in apoptosis was observed in these cells. Apoptotic ability was more enhanced and migration, proliferation, and invasion were more impaired in HBC cells treated with both miR-21-5p inhibitor and reversine than in those treated individually with either inhibitors. SPRY2, downstream of miR-21-5p, participated in HBC progression with reversine. Overall, our study proved that combining the miR-21-5p inhibitor with reversine produced a synergistic effect by regulating SPRY2, thereby limiting HBC progression. This knowledge might offer insights into the clinical therapy of HBC.

Indexed as

AnimalsAntagomirsBreast NeoplasmsCell Line, TumorCell MovementCell ProliferationDrug SynergismFemaleHumansIntracellular Signaling Peptides and ProteinsMCF-7 CellsMembrane ProteinsMiceMicroRNAsMorpholinesNeoplasm Staging2-(4-morpholinoanilino)-6-cyclohexylaminopurineAntagomirsIntracellular Signaling Peptides and ProteinsMembrane ProteinsMicroRNAsMIRN21 microRNA, humanMorpholinesPurinesSPRY2 protein, humanHuman breast cancermiR-21-5preversineSPRY2

Identifiers

PMID34967265
PMCPMC8805969
OpenAlexW4200276695

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.